Second Generation Synthetic AFGP Tests Stable and Safe

VANCOUVER, British Columbia, May 19, 2005 (PRIMEZONE) -- The University of Rouen in France reports that their laboratory has completed an enzymatic study on the dimeric compound of synthetic AFGP, which resulted in zero degradation. This confirmation of the stability of the dimeric class of AFGP illustrates that the newly engineered molecule has maintained the same stable characteristic as the monomeric predecessor.

Dr. Geraldine Deliencourt reports today, from the laboratory at Rouen, that she has just received results from a cytotoxic (safety) study on the very sensitive vero (kidney) cells with the dimeric AFGP. The results showed the dimeric AFGP to be non-toxic in the same manner the monomeric AFGP tested. These confirmations of stability and non-toxicity are critically important for the successful commercialization of synthetic AFGP.

These findings allow ProtoKinetix (OTCBB:PKTX) to immediately commence testing this new compound (dimeric AFGP) on cell lines and tissues in France and Canada. Management anticipates that this advanced engineered molecule will exhibit superior results to the already successful monomeric synthetic AFGP. This second generation AFGP is a clear indication of the Company's ability to customize this molecule with desired characteristics to adapt to the cell line or tissue being preserved.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.

For more detailed information, please visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO

ProtoKinetix Inc.
Investor Contact
Blair Henderson, 604-687-9887